Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prolonged treatment with pegylated interferon alpha 2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan.
Watanabe S, Enomoto N, Koike K, Izumi N, Takikawa H, Hashimoto E, Moriyasu F, Kumada H, Imawari M; PERFECT Study Group. Watanabe S, et al. Among authors: koike k. Hepatol Res. 2010 Feb;40(2):135-44. doi: 10.1111/j.1872-034X.2009.00567.x. Epub 2009 Sep 25. Hepatol Res. 2010. PMID: 19788694
Evidence-based clinical practice guidelines for liver cirrhosis 2020.
Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Yoshiji H, et al. Among authors: koike k. Hepatol Res. 2021 Jul;51(7):725-749. doi: 10.1111/hepr.13678. Epub 2021 Jul 6. Hepatol Res. 2021. PMID: 34228859
Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020.
Tokushige K, Ikejima K, Ono M, Eguchi Y, Kamada Y, Itoh Y, Akuta N, Yoneda M, Iwasa M, Yoneda M, Otsuka M, Tamaki N, Kogiso T, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Tokushige K, et al. Among authors: koike k. Hepatol Res. 2021 Oct;51(10):1013-1025. doi: 10.1111/hepr.13688. Epub 2021 Sep 17. Hepatol Res. 2021. PMID: 34533266
Clinical practice guidelines for autoimmune hepatitis.
Ohira H, Takahashi A, Zeniya M, Abe M, Arinaga-Hino T, Joshita S, Takaki A, Nakamoto N, Kang JH, Suzuki Y, Sogo T, Inui A, Koike K, Harada K, Nakamoto Y, Kondo Y, Genda T, Tsuneyama K, Matsui T, Tanaka A. Ohira H, et al. Among authors: koike k. Hepatol Res. 2022 Jul;52(7):571-585. doi: 10.1111/hepr.13776. Epub 2022 May 25. Hepatol Res. 2022. PMID: 35533021 No abstract available.
Risk factors for relapse of autoimmune hepatitis in Japan: A nationwide survey.
Takahashi A, Ohira H, Abe K, Zeniya M, Abe M, Arinaga-Hino T, Nakamoto N, Takaki A, Kang JH, Joshita S, Suzuki Y, Koike K, Inui A, Tanaka A; Japan Autoimmune Hepatitis Study Group. Takahashi A, et al. Among authors: koike k. Hepatol Res. 2022 Jul;52(7):597-602. doi: 10.1111/hepr.13766. Epub 2022 Apr 13. Hepatol Res. 2022. PMID: 35355374
3,106 results